758 related articles for article (PubMed ID: 11103810)
1. Targeting of bivalent anti-ErbB2 diabody antibody fragments to tumor cells is independent of the intrinsic antibody affinity.
Nielsen UB; Adams GP; Weiner LM; Marks JD
Cancer Res; 2000 Nov; 60(22):6434-40. PubMed ID: 11103810
[TBL] [Abstract][Full Text] [Related]
2. Mono and bivalent binding of a scFv and covalent diabody to murine laminin-1 using radioiodinated proteins and SPR measurements: effects on tissue retention in vivo.
Huang BC; Davern S; Kennel SJ
J Immunol Methods; 2006 Jun; 313(1-2):149-60. PubMed ID: 16750217
[TBL] [Abstract][Full Text] [Related]
3. High affinity restricts the localization and tumor penetration of single-chain fv antibody molecules.
Adams GP; Schier R; McCall AM; Simmons HH; Horak EM; Alpaugh RK; Marks JD; Weiner LM
Cancer Res; 2001 Jun; 61(12):4750-5. PubMed ID: 11406547
[TBL] [Abstract][Full Text] [Related]
4. Bispecific tandem diabody for tumor therapy with improved antigen binding and pharmacokinetics.
Kipriyanov SM; Moldenhauer G; Schuhmacher J; Cochlovius B; Von der Lieth CW; Matys ER; Little M
J Mol Biol; 1999 Oct; 293(1):41-56. PubMed ID: 10512714
[TBL] [Abstract][Full Text] [Related]
5. Isolation of picomolar affinity anti-c-erbB-2 single-chain Fv by molecular evolution of the complementarity determining regions in the center of the antibody binding site.
Schier R; McCall A; Adams GP; Marshall KW; Merritt H; Yim M; Crawford RS; Weiner LM; Marks C; Marks JD
J Mol Biol; 1996 Nov; 263(4):551-67. PubMed ID: 8918938
[TBL] [Abstract][Full Text] [Related]
6. Increased affinity leads to improved selective tumor delivery of single-chain Fv antibodies.
Adams GP; Schier R; Marshall K; Wolf EJ; McCall AM; Marks JD; Weiner LM
Cancer Res; 1998 Feb; 58(3):485-90. PubMed ID: 9458094
[TBL] [Abstract][Full Text] [Related]
7. A diabody that dissociates to monomer forms at low concentration: effects on binding activity and tumor targeting.
Huang BC; Foote LJ; Lankford TK; Davern SM; McKeown CK; Kennel SJ
Biochem Biophys Res Commun; 2005 Feb; 327(4):999-1005. PubMed ID: 15652494
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics and biodistribution of genetically-engineered antibodies.
Colcher D; Pavlinkova G; Beresford G; Booth BJ; Choudhury A; Batra SK
Q J Nucl Med; 1998 Dec; 42(4):225-41. PubMed ID: 9973838
[TBL] [Abstract][Full Text] [Related]
9. A novel bispecific tetravalent antibody fusion protein to target costimulatory activity for T-cell activation to tumor cells overexpressing ErbB2/HER2.
Biburger M; Weth R; Wels WS
J Mol Biol; 2005 Mar; 346(5):1299-311. PubMed ID: 15713482
[TBL] [Abstract][Full Text] [Related]
10. Isolation of high-affinity monomeric human anti-c-erbB-2 single chain Fv using affinity-driven selection.
Schier R; Bye J; Apell G; McCall A; Adams GP; Malmqvist M; Weiner LM; Marks JD
J Mol Biol; 1996 Jan; 255(1):28-43. PubMed ID: 8568873
[TBL] [Abstract][Full Text] [Related]
11. Prolonged in vivo tumour retention of a human diabody targeting the extracellular domain of human HER2/neu.
Adams GP; Schier R; McCall AM; Crawford RS; Wolf EJ; Weiner LM; Marks JD
Br J Cancer; 1998 May; 77(9):1405-12. PubMed ID: 9652755
[TBL] [Abstract][Full Text] [Related]
12. Construction and characterization of novel, recombinant immunotoxins targeting the Her2/neu oncogene product: in vitro and in vivo studies.
Cao Y; Marks JD; Marks JW; Cheung LH; Kim S; Rosenblum MG
Cancer Res; 2009 Dec; 69(23):8987-95. PubMed ID: 19934334
[TBL] [Abstract][Full Text] [Related]
13. Cure of Burkitt's lymphoma in severe combined immunodeficiency mice by T cells, tetravalent CD3 x CD19 tandem diabody, and CD28 costimulation.
Cochlovius B; Kipriyanov SM; Stassar MJ; Schuhmacher J; Benner A; Moldenhauer G; Little M
Cancer Res; 2000 Aug; 60(16):4336-41. PubMed ID: 10969772
[TBL] [Abstract][Full Text] [Related]
14. Targeting and therapy of carcinoembryonic antigen-expressing tumors in transgenic mice with an antibody-interleukin 2 fusion protein.
Xu X; Clarke P; Szalai G; Shively JE; Williams LE; Shyr Y; Shi E; Primus FJ
Cancer Res; 2000 Aug; 60(16):4475-84. PubMed ID: 10969795
[TBL] [Abstract][Full Text] [Related]
15. Efficient growth inhibition of ErbB2-overexpressing tumor cells by anti-ErbB2 ScFv-Fc-IL-2 fusion protein in vitro and in vivo.
Shi M; Zhang L; Gu HT; Jiang FQ; Qian L; Yu M; Chen GJ; Luo Q; Shen BF; Guo N
Acta Pharmacol Sin; 2007 Oct; 28(10):1611-20. PubMed ID: 17883948
[TBL] [Abstract][Full Text] [Related]
16. The effect of variable domain orientation and arrangement on the antigen-binding activity of a recombinant human bispecific diabody.
Lu D; Jimenez X; Witte L; Zhu Z
Biochem Biophys Res Commun; 2004 May; 318(2):507-13. PubMed ID: 15120630
[TBL] [Abstract][Full Text] [Related]
17. Antigen binding and stability properties of non-covalently linked anti-CD22 single-chain Fv dimers.
Arndt MA; Krauss J; Rybak SM
FEBS Lett; 2004 Dec; 578(3):257-61. PubMed ID: 15589829
[TBL] [Abstract][Full Text] [Related]
18. 125I-labeled anti-epidermal growth factor receptor-vIII single-chain Fv exhibits specific and high-level targeting of glioma xenografts.
Kuan CT; Reist CJ; Foulon CF; Lorimer IA; Archer G; Pegram CN; Pastan I; Zalutsky MR; Bigner DD
Clin Cancer Res; 1999 Jun; 5(6):1539-49. PubMed ID: 10389943
[TBL] [Abstract][Full Text] [Related]
19. Improving the productivity of single-chain Fv antibody against c-Met by rearranging the order of its variable domains.
Kim YJ; Neelamegam R; Heo MA; Edwardraja S; Paik HJ; Lee SG
J Microbiol Biotechnol; 2008 Jun; 18(6):1186-90. PubMed ID: 18600066
[TBL] [Abstract][Full Text] [Related]
20. Epitope mapping and structural analysis of an anti-ErbB2 antibody A21: Molecular basis for tumor inhibitory mechanism.
Hu S; Zhu Z; Li L; Chang L; Li W; Cheng L; Teng M; Liu J
Proteins; 2008 Feb; 70(3):938-49. PubMed ID: 17847085
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
